Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2003

Van Rijnsoever Marius, Elsaleh Hany, Joseph David, McCaul Kieran, Iacopetta Barry

Abstract excerpt

PURPOSE: The CpG island methylator phenotype (CIMP) is observed in approximately 30% of colorectal cancer (CRC) cases and is characterized by the concurrent methylation of multiple CpG islands in tumor DNA. This phenotype (CIMP+) is more frequently observed in tumors with proximal location, micro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CpG Islands

Share to DNA Methylation

Share to Fluorouracil

Share to Genes, p53

Share to Multivariate Analysis

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 12912934

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-12912934-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.PMID 12912934Read ↗

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Semantic proximity Read ↗

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.Semantic proximity Read ↗

Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.Semantic proximity Read ↗

Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis.Semantic proximity Read ↗

CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.Semantic proximity Read ↗

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.Semantic proximity Read ↗

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.Semantic proximity Read ↗

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Semantic proximity Read ↗

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.Semantic proximity Read ↗

The role of the CpG island methylator phenotype on survival outcome in colon cancer.Semantic proximity Read ↗

Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.